Lionheart Health, a regenerative health and longevity technology company, has announced a strategic partnership with Rejuvant, developer of patented sustained-release Calcium alpha-ketoglutarate (CaAKG) supplementation, as part of Lionheart Health's participation in the XPRIZE Healthspan Semi-Finals. The company was selected as one of 40 semi-finalists from more than 600 entries in spring 2025. Under this collaboration, Rejuvant's CaAKG supplement—associated with peer-reviewed research demonstrating improvements in biological age markers—has been designated a mandatory core component of the Lionheart KLOTHO-UP™ Study and the broader Lionheart Klotho Wellness Program, both central to Lionheart's XPRIZE Healthspan initiative.
The Lionheart KLOTHO-UP™ Study integrates Rejuvant's CaAKG supplementation within a multi-modal healthspan optimization framework designed to evaluate coordinated improvements across muscle, metabolic, immune, cardiovascular, and brain health domains. In addition to Rejuvant CaAKG, all study participants receive SNiP Nutrition™ personalized supplements customized based on genetic and biomarker profiles, targeted Klotho-focused supplementation, and Lionheart Health's BodStim™ bioelectric exercise platform delivering Klotho- and follistatin-elevating electrical muscle stimulation-enhanced exercise sessions. This integrated approach reflects Lionheart's belief that meaningful healthspan extension requires both lifestyle optimization and advanced biological technologies working in concert.
All enrollees in the KLOTHO-UP™ Study and Klotho Wellness Program undergo extensive testing and evaluation at baseline, 3 months, 6 months, and 12 months, including a 461-biomarker comprehensive blood panel with klotho levels, AI-enhanced full-body MRI with targeted organ and tissue analysis, muscle health assessments, gut health and microbiome evaluation, breathing and sleep analysis, stress and inflammation profiling, blood sugar and metabolic regulation analysis, vascular and calcification assessment, joint health and mobility evaluation, sexual health assessment, vision and hearing evaluation, and brain health testing including cognition, memory, and mood metrics. This longitudinal design enables objective tracking of functional healthspan changes over time rather than reliance on single-endpoint or short-duration outcomes.
A spokesperson for Lionheart Health stated that Rejuvant's CaAKG platform represents one of the most rigorously studied nutritional interventions in the biological aging space, and by making CaAKG a mandatory core component of their XPRIZE Healthspan protocol, they are anchoring their program in validated metabolic biology while layering in advanced bioelectric, Klotho-focused, and personalized technologies. A representative from Rejuvant added that the collaboration allows CaAKG supplementation to be evaluated within one of the most comprehensive, biomarker-driven healthspan programs ever assembled. More information about the program is available at https://lionheartlongevity.com/treatment/klotho-wellness-program/.
The partnership represents a significant development in the longevity technology sector, combining multiple validated approaches to healthspan extension within a structured, measurable framework. The inclusion of Rejuvant's CaAKG supplement—backed by peer-reviewed research—within Lionheart's comprehensive platform could provide valuable data on synergistic effects between different longevity interventions. For the broader health and wellness industry, this collaboration demonstrates the growing trend toward integrated, multi-modal approaches to aging that combine nutritional interventions, personalized supplementation, bioelectric technologies, and extensive biomarker tracking. The outcomes from this XPRIZE Healthspan initiative could influence future standards for healthspan optimization programs and provide evidence for the effectiveness of combining multiple longevity technologies rather than relying on single interventions.
